Uromitexan

Mesna

Prevention of urotoxic effects of oxazaphosphorines.

Antineoplastic as IV bolus: Adult Uromitexan as 20% of the antineoplastic dose on a wt for wt basis given IV at 4-hrly intervals, beginning at the same time as the antineoplastic inj at 0, 4 & 8 hr. Childn Carry out administrations more frequently (eg, 6 times) & at shorter intervals (eg, 3 hr). Antineoplastic as continuous infusion: Uromitexan as 20% of the total antineoplastic dose given by IV inj, followed by 100% of the total antineoplastic dose by IV infusion over 24 hr, then followed by up to 50% by infusion over a further 12 hr.

Protective effect applies only to the urinary tract.

GI effects, headache, malaise, skin rash. Allergic symptoms (rare). Vein irritation.

Antidotes & Detoxifying Agents / Supportive Care Therapy

V03AF01 - mesna ; Belongs to the class of detoxifying agents used in antineoplastic treatment.

G